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 Infection of four baboons with Trypanosma brucei gambiense resulted in a prepatent period of 3 – 4 days.  
Following the first appearance of T. b. gambiense parasitaemia, the animals developed trypanosomosis characterised 
by elevated parasite counts in the blood, fever, increased heart and respiratory rates and increased capillary refill 
time.  The disease was also associated with pallor of visible mucous membranes, oedema, increased reticulocyte 
counts, progressive decline in erythrocyte indices (RBC, Hb and PCV), consistent monocytosis, and leucopenia due to 
lymphopenia and neutropenia.  These clinical signs and widespread pathological changes seen in the liver, kidney, 
lymph nodes, heart and brain were progressive with the disease.  The disease also disrupted the circadian rhythmicity 
of sleep and wakefulness between weeks 8 and 10 when the animals were in the classical diurnal sleepiness with 8 - 
10 sleep episodes and nocturnal restlessness.  All the infected baboons died from the attendant disease between the 
8 and 10 weeks of infection.  Treatment with Berenil or DFMO at 4 weeks post infection reversed most of the clinical, 
haematological and pathological changes, the CSF-WBC counts and cleared the parasites from the circulation of the 
infected baboons.  However, there was relapse parasitaemia by 18 and 20 weeks respectively post infection in the 
groups treated with DFMO and Berenil.  The results of this study suggest that baboons manifest similar clinical and 
pathological lesions as man infected with T. b. gambiense and might therefore be a useful model for the study of the 
human disease.  Furthermore, the results suggest the therapeutic usefulness of DFMO in the treatment of human and 
animal trypanosomosis due to T. b. gambiense. 
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INTRODUCTION 
 Human African trypanosomosis or sleeping 
sickness due to Trypanosoma brucei gambiense is a re-
emerging complex and debilitating disease of man.  It is 
prevalent in several areas of Central and West Africa 
(Solano et al., 2003; Grootenhuis, 2004).  The disease is 
zoonotic with many wild and domestic animals being 
identified as potential animal reservoir hosts (Abenga 
and Lawal, 2005; Simo et al., 2006; Njoukou et al., 
2006). 
 The Gambian sleeping sickness evolves 
through two clinically different stages; the early or 
haematolymphatic stage and the late or 
meningoencephalic stage characterised by central 
nervous system (CNS) disturbances (Poltera, 1985; 
Anonymous, 1998).  Both stages terminate in death 
when untreated (Camara et al., 2005; Chretien et al., 
2005).  Presently, there is no consensus on the 
diagnostic criteria for the various stages and especially 
for specific indications for therapy and follow up when 
the central nervous system (CNS) is invaded (Courtioux 
et al., 2005; Kennedy, 2006a, b). The problem of 
diagnosis is further complicated by the absence of a 
clear understanding of the clinical and pathological 





 The major drugs for the treatment of affected 
individuals are suramin and melarsoprol especially when 
the CNS is invaded (Erhardt et al., 2006).  However, as 
a result of the adverse and sometimes fatal reactions 
frequently associated with such treatments, several 
workers have tried DL-α-difluoromethyl ornithine 
(DFMO) as a therapeutic alternative (Onyeyili and Anika, 
1990; Boa et al., 1995; Khonde et al., 1995). 
 In this study, baboons (Papio anubis) were 
experimentally infected with Trypanosoma brucei 
gambiense (T. b. gambiense) and treated with DFMO to 
evaluate their possible usefulness as animal models for 
studying the Gambian sleeping sickness. 
 
MATERIALS AND METHODS 
 
Experimental Animals 
 Sixteen adult baboons of both sexes were used 
for this study. They were acquired from the Sanda 
Kyarimi Park, Maiduguri, Nigeria. The animals were 
routinely de-wormed orally with pyrantel permeate 
(Combantrim, Pfizer Ltd., USA) and treated with 
oxytetracycline hydrochloride against rickettsial 
organisms and Diminazene aceturate (Berenil) against 
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fly-proof room.  The animals were fed fresh fruits and 
vegetables while water was provided ad libitum.  They 
were allowed to acclimatize to their new environment 4 
weeks before the commencement of the experimental 
study.  The Research Committee of the Faculty of 
Veterinary Medicine, University of Maiduguri and the 
Borno State Department of Wildlife approved this 
experiment and the animals were handled in accordance 




 Trypanosoma brucei gambiense (strain 
NITR/Abraka) was used for the study.  The parasite was 
isolated from a human case of sleeping sickness at 
Abraka (southern Nigeria) in September 1990.   The 
isolates were confirmed to be T. b. gambiense using the 
serum incubation and infectivity test (Owen and Gillete, 
1992).  They were maintained by serial passages in rats 
and produced acute and sub-acute infections with a 
prepatent period of 2 – 4 days in donor baboons. 
Test drugs 
 DL- α – difluoromethyl ornithine (DFMO) was 
obtained from Meril Dow Research Institute, Ohio, USA 
in a white crystalline form.  In each case, a fresh 
preparation of the drug was administered for seven days 
at 300 mg/kg body weight as a 2% solution in drinking 
water.  To ensure adequate consumption of the drug, it 
was served when the ambient temperature was 
relatively high and completely consumed before normal 
drinking water was served to the animals.  Berenil 
(Diminazemne aceturate; Faewerke, A. G. Germany) 
was administered as a single intramuscular injection at 
3.5 mg/kg body weight.  In all cases, treatment of the 




 The baboons were divided into four groups (A, 
B, C and D) of four animals each.  The baboons in 
groups A, B and C were each infected intravenously with 
5 X 103 T. b. gambiense in baboon blood diluted in 
phosphate-buffered glucose saline.  The baboons in 
group A were treated with DFMO and group B with 
Berenil while those in group C remained untreated.  
Animals in groups D were uninfected and untreated and 
served as healthy control. 
 Each experimental group was housed 
separately and monitored daily for the development of 
clinical signs of trypanosomosis.  Live body weight, the 
degree of parasitaemia and changes in haematological  
 
 
parameters were assessed every two weeks.  The study 
lasted twenty weeks. 
 
Assessment of Drug Efficacy 
 
Clinical evaluation 
 Clinical parameters including rectal temperature, 
pulse and respiratory rates were monitored daily 
throughout the duration of the study. 
 
Determination of parasitaemia 
 Parasitaemia was first detected by daily 
examination of peripheral blood using the wet mount 
and buffy coat techniques (Murray et al., 1983).  The 
degree of parasitaemia was estimated every two weeks 




 Blood samples were collected every two weeks 
through the cephalic vein.  Packed cell volume (PCV) 
and the numbers of red blood cells (RBC), reticulocyte, 
total white blood cells (WBC) and differential WBC were 
estimated as described by Jain (1993). 
 Samples of the cerebrospinal fluid (SCF) were 
taken by lumber puncture between the 4th and 5th lumber 
vertebrae in all the experimental baboons.  The WBC 
and trypanosome counts were estimated every two 
weeks (Khonde et al., 1995). 
 
Gross and histopathological examinations 
 Necropsy of dead baboons and those humanely 
sacrificed at the end of the study was performed and 
tissue samples (liver, heart, lymph nodes, spleen, kidney 
and lungs) collected were fixed in 10% formal saline.  
The tissues were embedded in paraffin wax, cut at 5μ 
thickness and routinely stained with haematoxylin and 
eosin stain for histological examination and 





Trypanosoma brucei gambiense parasitaemia 
was first detected in all the infected groups of baboons 3 
– 4 days post infection.  In the infected/untreated group, 
parasite counts rose sharply to a peak 10 weeks post 
infection (Fig. 1).  Treatment with Bereni or DFMO 
resulted in significant reduction of parasite counts and 
by 8 and 10 weeks post infection, the parasites were 
respectively no longer detectable in blood in the two 
groups.  Relapse parasitaemia was however noted from 
18 and 20 weeks respectively post infection in the 






































 Following the first appearance of parasitaemia, 
all the infected baboons developed clinical 
trypanosomosis characterised by fever and increased 
heart and respiratory rates with prolonged capillary refill 
time.  In the infected/untreated group, these clinical 
signs were progressive and from 8 weeks post infection 
there were signs of fatigue, peri-orbital oedema and 
oedema of the hind quarters, bilateral submandibular 
lymphadenopathy and pallor of mucous membranes.  
Two baboons in this group convulsed and during this 
period there was somnolence (hypersomnia) with 8 – 10 
sleep episodes in day time and nocturnal insomnia.  All 
the baboons in this group died from the infection 
between week 8 (one baboon) and week 10 (three 
baboons).   
 Besides the initial signs of fever, treatment with 
either DFMO (Group A) or Berenil (Group B) suppressed 
the manifestation of the clinical signs of the disease and 
none of the baboons in either of this group died from the 
infection during the study period. 
 
Haematological observations 
 Following the first appearance of parasitaemia, 
there was precipitous decline in the RBC, PCV and Hb 
values of all the infected baboons (Figs. 2 and 3).  The 
decline in the values of these parameters continued 
unabated until death of all the baboons in the 
infected/untreated group by 10 weeks post infection.  On 
the other hand, treatment with DFMO or Berenil by week 
4 post infection resulted in a decline in the values of the 
erythrocyte indices or their increase towards pre-
infection values for the rest of the study period. 
  
 
 Following infection, the reticulocyte values of all 
the infected baboons showed a steady increase to a 
peak by 10 weeks post infection corresponding to the 
lowest level of the other erythrocyte indices and the 
death of all the animals in the infected/untreated group 
(Fig. 3).  In those groups treated with Berenil or DFMO, 
reticulocyte numbers continually declined from week 12 
but failed to reach their pre-infection levels at the end of 
the study.  In the healthy control group, reticulocyte 
counts did not vary significantly from their pre-infection 
levels throughout the study period. 
 Leucocyte counts of the healthy control group 
remained within their pre-infection values throughout the 
study (Fig. 4).  On the other hand, there was a gradual 
decline in the leucocyte numbers in all the infected 
groups from week 8 post infection.  In the group treated 
with DFMO and Berenil, leucocyte numbers reached 
their lowest levels by 10 and 12 weeks respectively post 
infection following which there was a continuous 
increase towards pre-infection levels.  These attempts 
toward recovery of the values were further aborted 
following the development of relapse parasitaemia in 
both groups.  The leucopeania was mainly due to 
lymphopenia and neutropenia.  There was however, a 
consistent monocytosis in all the infected baboons, 
including those treated with DFMO or Berenil. 
 Cerebrospinal fluid leucocyte (CSF – WBC) 
counts remained within the pre-infection values in the 
healthy control group throughout the study (Fig. 4).  On 
the other hand, there was a sharp increase in the CSF – 
WBC counts of all the infected baboon groups to a peak 
at week 10 when all the infected/untreated animals died 
from the infection.  Treatment with Berenil or DFMO 
resulted in a sharp and continuous decline in the CSF – 
WBC counts towards pre-infection values for the rest of 
the study period. 
 
     DFMO AND EXPERIMENTAL SLEEPING SICKNESS IN BABOONS                                                                                    71
Fig. 1: Mean parasitaemia of baboons infected with T.b.gambiense and 
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Necropsy findings 
 The gross lesions observed at necropsy in the 
baboons that died from the infection or those humanely 
sacrificed at the end of the study include varying 
severities of hepatomegaly, splenomegaly, 
submandibular lymphadenopathy, serous atrophy of 
pericardial, abdominal and perirenal fat and congestion 
of meningeal blood vessels. 
 Histological lesions included depletion and 
necrosis of lymphocytes and lymphophagocytosis by 
numerous macrophages and haemosiderosis in lymph 
nodes and spleen (Plate 1); pulmonary congestion and 
oedema, thickened inter-alveolar septa and 
mononuclear cellular infiltration and haemosiderosis in 
the lungs; sinusoidal congestion, periportal and 
centrilobular vacuolar degeneration and necrosis of 
hepatocytes, and mononuclear cell aggregations (Plate 
2); multifocal areas of hyaline degeneration of 
myocardial fibres; widespread glomerular and tubular 
degeration and the presence of proteinaceous casts in 
renal cortical tubulaes (Plate 3) and meningeal 
congestion and non-suppurative meningo-encephalitis.  
These lesions were generally more severe in the 
infected/untreated baboons but only mild to moderate in 






Plate 1: Spleen of baboon (Papio anubis) infected with Trypanosoma brucei gambiense and untreated showing widespread  






Plate 2: Liver of baboon (Papio anubis) infected with Trypanosoma brucei gambiense and treated with Berenil® showing  
 widespread vacuolar degeneration and necrosis of hepatocytes, and mononuclear cell aggregations (H&E; x500) 
 








Plate 3: Kidney of baboon (Papio anubis) infected with Trypanosoma brucei gambiense and treated with DMFO showing   




 The results of this study showed that DFMO at 
the dose of 300 mg/kg body weight used in this study 
reversed the morbidity and mortality of baboons infected 
with T. b. gambiense.  The observed reversal of the 
clinical manifestations, haematological and pathological 
changes with a clearance of the parasites from the 
circulation of the infected baboons is consistent with 
earlier reports in humans naturally infected with the 
parasite (Spinazzola et al., 1990; Boa et al., 1995; 
Khonde et al., 1995).   
The acute course of the infection in the baboons 
mimicked the course of experimental T. b. brucei 
infection in animals (Losos and Ikede, 1972; Nwosu and 
Ikeme, 1992).  Similar observations were made in 
natural infections of man (Ford, 1971) and experimental 
infections of vervet monkeys (Abenga and Anosa, 2006) 
with the parasite.  The same strain of parasite had 
earlier produced similar acute manifestations in human 
outbreaks of sleeping sickness at Abraka in southern 
Nigeria (Edeghere et al., 1989; Enwezor and Ukah, 
2000).  However, the acute nature of the present study 
differed significantly from the typical chronic disease 
usually seen in man (Picozzi et al., 2005). 
 Anaemia is the commonest feature of African 
animal and human trypanosomosis (Anosa, 1983; Losos 
and Ikede, 1972; Nwosu and Ikeme, 1992).  In the 
present study, anaemia associated with significant 
reductions in the values of erythrocyte indices (RBC, 
PCV and Hb) was recorded in the infected baboons.  
Abenga and Anosa (2004) made the same observations 
in vervet monkeys experimentally infected with T. b. 
gambiense.  According to Anosa (1988), the anaemia of 
trypanosomosis is related to the severity of the attendant 
disease; acute diseases being associated with 
precipitous drops in erythrocyte indices without 
abatement until death of the infected animals.  A similar 
pattern of anaemia occurred during this study, as the 
reductions in erythrocyte indices were more precipitous 
and continued until death of the untreated baboons.  
However, treatment with Berenil or DFMO and the 
consequent clearance of the parasites from the 
circulation reversed this trend with eventual appreciation 
in the values of these parameters towards their pre-
infection levels. 
 There was evidence of erythropoietic response 
in the femoral marrow as manifested by the consistent 
reticulocytosis recorded in the infected baboons.  
However, reticulocyte response was more marked in the 
early part of the disease when the baboons also 
manifested greater anaemia than after treatment with 
DFMO or Berenil.  Earlier reports showed that 
erythropoietic responses in animals infected with 
trypanosome species was related to the degree of 
anaemia (Igbokwe and Mohammed, 1991; Nwosu and 
Ikeme, 1992; Abenga and Anosa, 2006). 
 The bilateral inflammation of the frontal lobes of 
the brain as noted in this study were associated with 
leuco-encephalitis and have been reported in human 
infections with trypanosome species (Spinazzola et al., 
1990).  According to Pentreath (1995), the breakdown of 
the choroids plexus during the later part of 
trypanosomosis compromises the blood-brain barrier 
with a resultant movement of the parasites into localised 
areas of the brain.  A similar pathogenesis may have 
occurred during this study as the intra peritoneal 
injection of homogenates of the brain from the relapsed 
baboons produced parasitaemia in recipient albino rats.  
On the other hand, homogenates of other tissues 
including the liver, heart, kidney and lymph nodes of the 
same baboons failed to produce parasitaemia in 
recipient albino rats after 21 days. At this point, 
treatment with DFMO or Berenil had cleared the 
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parasites from the circulation and the CSF and had 
significantly reduced the CSF – WBC counts.  Similar 
observations were made in dogs infected with T. b. 
brucei (Chukwu et al., 1990) and in human infections of 
T. b. gambiense (Nantulya et al., 1992).  Consequently, 
the parasites responsible for the relapse infection must 
have originated from the localised areas of the brain.  
 At the meningo-encephalitis (ME) stage, African 
sleeping sickness has been reported to cause a 
disruption of the circadian rhythmicity of sleep and 
wakefulness (Buguet et al., 1989; 2005).  Similar 
observations were made in the present study.  The 
baboons were in the ME stage between the 8th and 10th 
weeks of infection and manifested 8 – 10 sleep episodes 
during the day thus conforming with the classical diurnal 
sleepiness and nocturnal wakefulness earlier reported in 
man (Ford, 1971; Buguet et al., 1989, 2005) and vervet 





 In conclusion therefore, the results of this study 
show that baboons manifest similar clinico-pathological 
features as man infected with T. b. gambiense 
suggesting the possible usefulness of the baboon as a 
good model for the study of the Gambian sleeping 
sickness.  The results further suggest the efficacy of 
DFMO in the treatment of the Gambian sleeping 
sickness.  However, the relapse parasitaemia observed 
from week 18 post infection of the treated animals 
constitute a serious draw back in the usefulness of this 
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